-
-
Call more information
660-596-2224 -
Authors: T. Andrew Bowdle, M.D., Ph.D., F.A.S.E. et al Anesthesiology July 2023, Vol. 139, 6–15. Background The dose of sugammadex recommended by the manufacturer for reversal of rocuronium is 2 mg/kg when the train-of-four count is 2 or more and 4 mg/kg when it is less than 2 but there is a posttetanic count of at least 1. […]
Read MoreAuthors: Patrick Forrest, MD et al ASA Monitor July 2023, Vol. 87, 1–5. Many readers may now be familiar with the new ASA practice guidelines for monitoring and antagonism of neuromuscular blockade that were published this past January (Anesthesiology 2023;138:13-41). For those who are not, this article may serve as a brief overview of the advances […]
Read MoreASA Monitor April 2023, Vol. 87, 17. UpToDate® and ASA Monitor are collaborating to present select content abstracts on “What’s New in Anesthesiology.” UpToDate is an evidence-based, clinical support resource used worldwide by health care practitioners to make decisions at the point of care. For complete, current “What’s New” content, or to become a subscriber for full content access, […]
Read MoreASA Monitor July 2023, Vol. 87, 10. A 45-year-old woman is scheduled to undergo a bilateral mastectomy for metastatic breast cancer. According to a recent study of patients undergoing breast cancer surgery with general anesthesia maintained with propofol or volatile agents, which of the following MOST likely describes overall survival with use of propofol compared to […]
Read MoreASA Monitor July 2023, Vol. 87, 7. Which of the following immunosuppressive drugs is MOST likely to cause renal dysfunction? □ (A) Tacrolimus □ (B) Mycophenolate mofetil □ (C) Basiliximab Immunosuppressant drugs are used to prevent or treat allograft rejection. Most of these drugs act during the induction phase of the immunological response, reducing lymphocyte proliferation. Some of them […]
Read More